Table 1.

Study Eligibility Criteria

Component	Description
Population	Adults and children with type 1 or type 2 diabetes
Intervention	Pramlintide for FDA- and non-FDA-approved indications
Compared agent	Other hypoglycemic agent or placebo
Long-term health outcomes	All-cause mortality, micro- or macrovascular disease, quality of life, complications related to diabetes
Intermediate outcomes	Glycemic control: HbA1c, fasting plasma glucose, postprandial glucose; change in weight; time to treatment failure
Harms-related outcomes	Withdrawals due to all causes, withdrawals due to adverse events, overall adverse events, major adverse events
Study design	For efficacy/effectiveness: randomized controlled clinical trials, good-quality systematic reviews For harms and subgroups: randomized controlled clinical trials, good-quality systematic reviews, population-based comparative cohort or case-control studies
Excluded	Trials <12 weeks’ duration; abstracts, posters, and conference proceedings with limited information for quality assessment

FDA = Food and Drug Administration; HbA_1c=glycated hemoglobin.